Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA3 | P07451 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963271 | 0.86 | KDM4E (0.53) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL28632856 | 0.80 | CA9 (0.58) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL1602863 | 0.80 | CA12 (0.58) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL17874149 | 0.79 | CA12 (0.59) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL28819309 | 0.77 | ALDH1A1 (0.58) | KDM4EHSD17B10ALDH1A1HPGDCA12 | |
| SCHEMBL18305548 | 0.77 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL719714 | 0.74 | ALDH1A1 (0.59) | KDM4EHSD17B10ALDH1A1HPGDCA12 | |
| SCHEMBL8405342 | 0.73 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1ALDH1A1 | |
| SCHEMBL28033663 | 0.73 | ALDH1A1 (0.58) | KDM4EHSD17B10ALDH1A1HPGDCA12 | |
| SCHEMBL18725071 | 0.73 | ALDH1A1 (0.58) | KDM4EHSD17B10ALDH1A1HPGDCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2018140513-A1 | 1-(3-(6-(3-HYDROXYNAPHTHALEN-1-YL)BENZOFURAN-2-YL)AZETIDIN-1YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C MODULATORS FOR TREATING CANCER | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180022750-A1 | 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | US | disclosed |
| EP-3237417-A1 | 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102427-A1 | 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016000599-A1 | C-BENZO FIVE-MEMBERED HETEROAROMATIC RING ARYL GLUCOSIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2016-01-07 | — | — | WO | disclosed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022750-A1 | 6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, KDR, FLT4 | KDM4E 1400/4885HSD17B10 808/4885MGLL 3564/4885 |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | KDM4E 221/4885HSD17B10 3351/4885MGLL 4829/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | KDM4E 413/4885HSD17B10 3857/4885MGLL 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.